Title

Specifically Targeting the CD22 Receptor of Human B-cell Lymphomas with RNA Damaging Agents

Authors

Dianne L. Newton, National Cancer Institute
Hans J. Hansen, Immunomedics
Huaitian Liu, National Cancer Institute
Dale Ruby, National Cancer Institute
Mihail S. Iordanov, Oregon Health Sciences UniversityFollow
Bruce E. Magun, Oregon Health Sciences University
David M. Goldenberg, Garden State Cancer Center
Susanna M. Rybak, National Cancer Institute

Document Type

Article

Publication Date

1-1-2001

Abstract

Targeting CD22 on human B-cells with a monoclonal antibody conjugated to a cytotoxic RNAse causes potent and specific killing of the lymphoma cells in vitro. This translates to anti-tumor effects in human lymphoma models in SCID mice. RNA damage caused by RNAses could be an important alternative to standard DNA damaging chemotherapeutics. Moreover, targeted RNAses may overcome problems of toxicity and immunogenicity associated with plant or bacterial toxin containing immunotoxins.

Comments

Publication Information.

Newton, D. L., Hansen, H. J., Liu, H., Ruby, D., Iordanov, M. S., Magun, B. E., Goldenberg, D. M., & Rybak, S. M. (2001). Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents. Critical Reviews in Oncology/Hematology, 39(1-2), 79-86. doi:10.1016/S1040-8428(01)00116-0

Published In

Critical Reviews in Oncology/Hematology

Recommended Citation

Newton, Dianne L.; Hansen, Hans J.; Liu, Huaitian; Ruby, Dale; Iordanov, Mihail S.; Magun, Bruce E.; Goldenberg, David M.; and Rybak, Susanna M., "Specifically Targeting the CD22 Receptor of Human B-cell Lymphomas with RNA Damaging Agents" (2001). CUP Faculty Research. 107.
https://digitalcommons.csp.edu/cup_commons_faculty/107

Source

CU Commons -- Math and Science Department Faculty Research